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Conclusions Screening sensitivity for detection of malig-
nant calcifications is low. Improving the detection of these 
early signs of cancer is important, because the majority of 
lesions with detectable calcifications that are not recalled 
immediately but detected as interval cancer or in the next 
screening round are invasive at the time of diagnosis.
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Introduction
The purpose of breast cancer screening is to detect cancer 
as early as possible [1, 2]. The earliest signs of non-palpable 
breast cancer are calcifications, which are usually associated 
with ductal carcinoma in situ (DCIS) but can also be present 
in invasive cancers [3]. In screening programs, between 12.7 
and 41.2% of women are recalled with calcifications as the 
only sign of cancer [4–7].
The Breast imaging reporting and data system (BI-
RADS) [8] was designed by the American College of Radi-
ology to standardize breast imaging reporting and to provide 
clarity on the interpretation of breast imaging studies. A 
set of guidelines is supplied in the BI-RADS atlas for the 
interpretation of calcifications, aiding the radiologist in dis-
tinguishing suspicious calcifications from typically benign 
changes, such as vascular and skin calcifications. It is recom-
mended to recall patients with suspicious calcifications for 
further clinical assessment, such as a biopsy [8, 9]. This can 
inadvertently lead to false positive outcomes, since calcifica-
tions associated with benign disease often look suspicious.
The vast majority of cancers detected by calcifications 
are DCIS, of which < 20% are low grade [10, 11]. In the 
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discussion about the pros and cons of breast cancer screen-
ing, detection of low-grade cancers is generally regarded as 
overdiagnosis [11, 12], since the detection of these cancers 
does not impact mortality reduction [13]. However, it is not 
possible to radiologically distinguish calcifications asso-
ciated with low-grade DCIS from more aggressive forms 
(grade II and III) in mammography, while these forms 
should be detected as early as possible [13–15]. There-
fore, radiologists in breast cancer screening are instructed 
to recall all suspicious calcifications. However, in practice, 
especially in countries where screening programs pursue 
very low recall rate (i.e., the percentage of screening exams 
that are recalled in screening) [16], radiologists do not recall 
patients with calcifications without the reasonable likelihood 
that they represent DCIS. In such scenario, interpretation of 
calcifications depends more on the training, experience, and 
skill of the screening radiologists in a dual reading setting.
There are many studies in which screening mammograms 
have been retrospectively evaluated to determine the sensi-
tivity of the screening in detecting breast cancer [17–28]. 
For instance, Vitak [19] re-examined screening exams per-
formed prior to the diagnosis of 544 interval cancers, i.e., 
cancers diagnosed between screening exams usually due to 
symptoms, reporting that 25% of these patients could have 
been recalled based on the screening mammogram. Destou-
nis et al. [25] have found that cancer was visible in 31% of 
318 exams prior to a later screen detection, while Burhenne 
et al. [28] have shown that cancer was visible in 67% of 427 
such cases. Broeders et al. [24] have shown that half of 234 
screen-detected and interval cancers were already visible on 
a prior exam. Other studies have reported that around 40% 
of screen-detected cancers could be detected on a previous 
exam [18, 23, 29]; however, note that all the aforementioned 
studies have been performed on screen-film mammography 
results and cannot be directly compared to digital mam-
mography, the current acquisition standard in breast cancer 
screening. Several studies have shown that recall rates and 
cancer detection rates resulting from suspicious calcifica-
tions differ significantly between screen-film or digital mam-
mography [6, 30]. Studies by Knox et al. [26] and Weber 
et al. [27], in which digital mammography screening per-
formance was assessed, have reported that between 10.5 and 
31% of interval cancers were missed in screening.
In most of these studies, no distinction was made 
between soft tissue lesions and calcifications, and gen-
erally only interval cancers were evaluated to determine 
false negatives. However, cancers that were detectable but 
missed in a prior screening can also be considered as false 
negatives. In this study, we include false negatives on prior 
mammograms of both screen-detected and interval can-
cers. We focus on earlier detection of calcifications, which 
can prevent the development of invasive disease. A better 
understanding of this phenomenon is not only relevant in 
relation to interval cancers, but also to screen-detected 
cancers, independent of the threshold used for recall.
The purpose of this study is to estimate how often 
malignant calcifications are not detected in a population-
based screening program with double reading, and to 
determine the proportion of invasive cancers detected by 
the presence of calcifications that were not recalled in the 
previous screening round. For this purpose, an accurate 
assessment of the presence of calcifications in mammo-
grams was performed in a large screening cohort using a 
computer-aided detection (CAD) system, in combination 
with visual inspection by an experienced radiologist. This 
provided a solid ground truth for the analysis. This also 
allowed us to accurately assess the sensitivity of screen-
ing for calcifications associated with breast cancer, in 
programs equipped with modern digital mammography 
systems.
Materials and methods
Materials
All data used in this study were collected from a single 
region of the Dutch Breast Cancer Screening Program 
(Bevolkings Onderzoek Midden-West, The Netherlands). 
In the Dutch Breast Cancer Screening Program, women 
between the age of 50 and 74 are biennially invited for a 
screening exam. This database contained all of the avail-
able screening exams, consisting of medio-lateral oblique 
and cranial–caudal views of the left and right breasts, from 
all screened women between 2003 and 2014. All images 
were acquired with full-field digital mammography sys-
tems (Hologic, Bedford, Massachusetts, United States). 
After acquisition, two radiologists independently assessed 
the mammogram and scored both breasts according to the 
BI-RADS. When there is a discrepancy between scores, 
a consensus meeting is held and when no consensus is 
reached, a third radiologist breaks the tie [31]. Women 
with BI-RADS 4 or 5 are recalled for further investigation.
An overview of the screening database is shown in 
Fig.  1. During the study period, 63,895 women (age 
59 ± 7) participated in the screening program (with a total 
of 170,878 screening exams). In 59,690 women, no abnor-
malities were found in any of their screening exams. A 
total of 3792 women were recalled for diagnostic follow-
up, of whom 979 had breast cancer. The remaining 2813 
recalled women were false positives, of whom 781 were 
recalled based on calcifications only. In 413 women, an 
interval cancer was found between screening exams.
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Methods
To construct the ground truth, we identified all women in 
our database with a pathologically proven invasive and non-
invasive breast cancer for whom a negative prior screening 
exam was available in addition to the screening mammogram 
that led to the detection of the cancer. Furthermore, we iden-
tified all negative screening exams prior to interval cancers, 
and all exams that were recalled solely based on calcifica-
tions but were pathologically proven to be benign. Exams of 
women without any abnormalities were included as well. We 
excluded women who were recalled multiple times (n = 49) 
or those who were recalled and later diagnosed with an inter-
val cancer (n = 11), to avoid complications in the analysis. 
The data included in this study are highlighted in Fig. 1.
To determine the ground truth regarding the presence of 
mammographically visible calcifications associated with 
cancer, we used radiology and pathology reports and a retro-
spective review of negative prior exams by a radiologist with 
more than 25 years of experience in reading mammograms 
and more than 15 years certified as a screening radiologist. 
To reduce the subjectivity and workload of the radiologist, a 
state-of-the-art CAD system [32, 33], operating at its highest 
sensitivity, was first applied to all mammograms of women 
with a screen-detected or an interval cancer. The CAD sys-
tem was developed in house, but we took care that mam-
mograms used to train the system were not included in the 
study dataset to avoid bias. This training set comprised less 
than 1% of the total number of normal exams in the screen-
ing database and less than 3% of the screen-detected cancers 
with a prior exam. Before the radiologist inspected the cases, 
an initial visual inspection by a researcher with experience 
in reading mammograms was carried out to exclude false 
positive CAD findings that were obviously not related to 
the recalled malignancies such as detected noise or vascular 
calcifications. The radiologist visually inspected the remain-
ing exams to determine whether they were related to the 
later diagnosis of screen-detected or interval cancer. Prior 
exams of screen-detected cancers were visually inspected 
together with the subsequent screening mammogram and 
radiology reports in which the cancer was detected. For the 
interval cancers, diagnostic mammograms and radiology 
reports were not available because the anonymized data in 
the database could not be linked to the hospitals where the 
assessment took place. Only the laterality of the interval 
cancer was known. The visual assessment was performed on 
a 12MP Coronis Uniti mammography monitor (Barco N.V., 
Kortrijk, Belgium).
Fig. 1  Overview of the breast cancer screening database used in this study, with data from 2003 to 2014. In this study, we include 170,878 
screening exams from 63,895 women. Boxes with a gray glow were included in the ground truth for the evaluation
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In the constructed database, the number of exams with 
detectable calcifications was determined for the false nega-
tive exams, which contained visible calcifications related 
to the cancer prior to the diagnosis of a screen-detected 
cancer (nprior) or an interval cancer (ninterval). The number 
of exams with detectable calcifications was also deter-
mined for the true positive screening exams, which did 
not have visible calcifications in the prior exam (nSD). In 
this way, each woman with malignant calcifications was 
represented only once in the series. The screening sensitiv-
ity for detecting calcifications associated with cancer was 
calculated as follows:
The proportion of invasive and non-invasive cancers at 
the time of detection was calculated to assess how often 
women with calcifications at the site of the detected cancer 
were diagnosed with invasive cancers. The invasive status 
of each cancer was obtained from the pathology reports. 
Finally, to analyze tumor size at the time of detection, the 
Sensitivity =
n
SD
nSD + nprior + ninterval
100%.
tumor stage (as T1, T2, or T3 [34]) was also collected for 
all invasive cancers.
Results
Exams of all 744 screen-detected cancers and 1157 exams 
obtained prior to a screen-detected or interval cancer were 
processed with the CAD system. In 536 of the 1157 prior 
exams, the CAD system detected at least one instance of 
calcifications. Of these, the researcher classified 112 as obvi-
ous false positives that were not related to the cancer. CAD 
findings in the remaining 434 exams were visually inspected 
by the radiologist, who determined that 177 exams contained 
calcifications related to cancer. Figure 2 shows three exam-
ples of non-recalled screening exams with calcifications: (1) 
prior to a screen-detected cancer with calcifications, (2) prior 
to a soft tissue lesion, and (3) prior to an interval cancer.
By including the calcifications detectable in prior 
exams, we identified 325 exams with calcifications asso-
ciated with malignancy in our dataset. Of these exams, 
45.5% (nSD  =  148) had calcifications that were only 
detectable at the time of the recall. The remaining 54.5% 
Fig. 2  Examples of calcifications detectable on prior mammograms. 
The top row contains examples of exams prior to screen-detected 
cancer with calcifications (first column), prior to a soft tissue lesion 
(second column), and prior to an interval cancer (third column). In 
each exam, a radiologist identified detectable calcifications related to 
the cancer. In the bottom row, the same locations are shown as above, 
focusing on where the cancer and soft tissue lesions were detected 
(first and second column, respectively)
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(nprior + ninterval = 177) were detectable in the previous nega-
tive mammograms: 36.3% (nprior = 118) on exams prior to a 
positive screening exam and 18.2% (ninterval = 59) on exams 
prior to an interval cancer. An overview of the distribution 
of these prior exams is shown in Table 1. These numbers 
were used to compute the sensitivity for the detection of 
calcifications associated with breast cancer in digital mam-
mogram screening; the screening sensitivity for malignant 
calcifications was calculated to be 45.5%. The specificity of 
malignant calcification detection, which was calculated from 
166,673 exams without abnormalities and 781 false positive 
exams with calcifications, was 99.5%. This means that only 
0.5% of the exams were falsely recalled in screening based 
on calcifications alone.
Table 2 summarizes the invasive status of the cancers. 
Of the 148 screen-detected cancers detected with calcifica-
tions, but without visible calcifications on the prior exam, 
77 (52.4%) were invasive. Of the screen-detected cancers 
with calcifications visible in the prior exams, 71 (60.2%) 
were invasive when they were detected in the following 
screening round (i.e., two years later). Of the interval 
cancers with visible calcifications in the negative prior 
mammogram, 50 (84.7%) were invasive once they were 
detected. Overall, of all the 177 detectable calcifications 
associated with cancer from the prior exams, 121 (68.4%) 
developed into an invasive disease.
The tumor stage for all invasive cancers with detect-
able calcifications is shown in Table 3. Of the screen-
detected cancers detected by calcifications with negative 
prior exams, 22.1% were stage T2 or T3. For the invasive 
cancers detectable by calcifications on the exam prior to 
a recall or prior to an interval cancer, the percentage at 
tumor stage T2 and T3 were 25.3 and 40.0%, respectively. 
For all cancers that could have been detected earlier from 
their associated calcifications, the percentage of invasive 
cancers at tumor stage T2 or T3 was 31.4%. The tumor 
stage was not available for 11 invasive cancers. 
Table 1  Overview of the 
prior exams included in the 
ground truth. A CAD system 
was applied to each prior 
exam. Only the exams with 
calcifications found in the 
same region as the cancer 
were visually assessed by a 
radiologist, who identified 
calcifications related to cancer
Assessment of calcifications related 
to cancer in prior exams
Prior exams 
available
Prior exams assessed 
by radiologist
Prior exams with 
calcifications related to 
cancer
Prior to screen-detected cancer 744 222 118
Prior to interval cancer 413 212 59
Total number of prior exams 1157 434 177
Table 2  Distribution of 
invasive and non-invasive 
cancers for all screen-detected 
calcifications and for all cancers 
with calcifications detectable in 
exams prior to screen-detected 
or interval cancer diagnosis
Distribution of invasive and non-invasive 
cancers
Total number of detect-
able cancers
Invasive Non-invasive
Screen-detected calcifications 148 77 (52.4%) 71 (47.6%)
Earlier-detectable calcifications associated 
with cancer, prior to
Total number of detectable 
cancers
Invasive Non-invasive
Screen-detected malignancies 118 71 (60.2%) 47 (39.8%)
Interval cancers 59 50 (84.7%) 9 (15.3%)
Total earlier‑detectable cancers 177 121 (68.4%) 58 (31.6%)
Table 3  Distribution of the tumor stages for invasive cancers with calcifications
Distribution of tumor stages Total number of  
invasive cancers
Stage T1 (< 2 cm) Stage T2 (2–5 cm) Stage T3 (> 5 cm) Unknown
Screen-detected calcifications 77 59 (76.6%) 15 (19.5%) 2 (2.6%) 1 (1.3%)
Earlier-detectable calcifications 
associated with cancer, prior to:
Total number of  
invasive cancers
Stage T1 (< 2 cm) Stage T2 (2–5 cm) Stage T3 (> 5 cm) Unknown
Screen-detected malignancies 71 51 (71.8%) 17 (23.9%) 1 (1.4%) 2 (2.8%)
Interval cancers 50 22 (44.0%) 18 (36.0%) 2 (4.0%) 8 (16.0%)
Total earlier‑detectable cancers 121 73 (60.3%) 35 (28.9%) 3 (2.5%) 10 (8.3%)
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Discussion
In this study, we determined the sensitivity of a population-
based screening program with double reading for calcifica-
tions associated with breast cancer using digital mammog-
raphy. By considering all detectable malignant calcifications 
visible in exams prior to a screen-detected or an interval 
cancer diagnosis, we found that the screening sensitivity for 
malignant calcifications in the studied program was only 
45.5%, while the specificity for calcifications was 99.5%. 
Because double reading is practiced in the screening pro-
gram, we believe that it is unlikely that the generally low 
sensitivity is caused by the oversight of the radiologists; 
instead, it is more likely that these results reflect a high 
threshold in the judgment of the radiologists when charac-
terizing calcifications as suspicious or unimportant.
This high threshold for recalling calcifications as a strat-
egy to minimize overdiagnosis should perhaps be revised. 
We found that 68.4% of the women with cancer who had 
calcifications in a negative prior screening mammogram had 
developed an invasive cancer by the time it was detected. 
This could suggest that lowering of the threshold for recall 
in the national screening program is justifiable because more 
invasive cancers could be detected earlier. The frequency of 
invasive disease in women recalled with calcifications that 
were not detectable in prior images was 52.4%.
This finding indicates that in screening programs with a 
low recall rate, earlier detection of the calcifications visible 
in prior exams might prevent up to 16% of cancers from 
becoming invasive. Earlier detection would also reduce the 
occurrence of more advanced cancers; 31.4% of the invasive 
cancers with calcifications detectable on a prior exam pre-
sented as a stage T2 or T3 disease, i.e., the cancer was larger 
than 20 mm, at the time of diagnosis, compared to 22% when 
no calcifications were present in the prior exam.
In this study, we found that 54.5% of the screen-detected 
and interval cancers were detectable by calcifications in 
exams prior to diagnosis. In previous studies, it was found 
that 31–67% of screen-detected cancers could have been 
identified in earlier mammograms and 10–31% of the 
interval cancers were visible in prior screenings [17–28]. 
In our study, the percentage of cancer-related calcifica-
tions detectable on an exam prior to the later diagnosis of 
screen-detected cancers was 44, and 14% of the exams prior 
to interval cancer diagnoses contained detectable calcifica-
tions related to the cancer. These percentages are within the 
ranges reported in the literature; however, since previous 
studies did not make a distinction between calcifications and 
soft tissue lesions when calculating the number of cancers 
that could have been detected earlier, the results cannot be 
compared directly. Moreover, most previous studies were 
performed with screen-film mammography rather than digi-
tal mammography, which can have a different effect on the 
recall and cancer detection rates, especially for recalls based 
on calcifications [6, 30].
We constructed the ground truth by applying a CAD 
system for the detection of calcifications in the prior mam-
mograms, followed by visual inspection by an experienced 
radiologist to determine the presence of calcifications related 
to the cancer detected later. The main purpose of using CAD 
was to reduce the workload of the radiologist and to make 
his judgment more objective. Because the CAD system was 
very sensitive, one could argue that use of a CAD system in 
screening could improve detection; however, current com-
mercial CAD systems only provide mark regions for further 
attention to avoid calcifications being overlooked. For the 
detection of all calcifications in the ground truth, the speci-
ficity of the CAD system was only 51% when applied to the 
whole screening database and for the setting at which it was 
used. It should be noted that this specificity was achieved 
by considering all CAD marks irrespective of their scores; 
therefore, increasing the threshold on these scores could 
increase the specificity of the CAD system but reduce its 
maximum sensitivity. While this setting may be appropri-
ate for use of CAD as a perception aid, it leaves the diffi-
cult problem of deciding which women with calcifications 
the radiologists should recall. To increase the role of CAD 
in calcification characterization algorithms, these systems 
should be developed to find an acceptable balance between 
sensitivity and specificity that would best help radiologists to 
stratify calcifications by risk. Previous studies have already 
demonstrated that CAD algorithms outperform radiologists 
in this task and there is potential to improve them consider-
ably using new machine learning techniques [32, 33, 35–41].
A limitation of this study is that we do not know how 
many negative exams did contain calcifications. Negative 
exams will contain many benign calcifications and most 
likely also some malignant calcifications that did not yet 
result in a diagnosis of cancer within the two-year follow-up 
period we used for verification. Sometimes, benign calci-
fications are categorized as BI-RADS 2, but they are not 
always reported. It would be interesting to study how often 
benign calcifications occur that look suspicious but were not 
recalled, and to compare them to the malignant calcifica-
tions that were missed in screening. However, in this study, 
visual assessment of the large number of negative exams was 
not performed. Therefore, we cannot assess to what extent 
a higher recall of suspicious calcifications would lead to a 
strong increase of false positives.
Another limitation of our study is that we did not have 
access to information of all interval cancers in the period 
between 2013 and 2014. The absence of these cases and 
the exclusion of 60 cases with multiple recalls may have 
had a small effect on the results we present. The missing 
interval cancer information, as well as the absence of the 
radiology reports for interval cancers, can only lead to an 
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underestimation of the number of detectable malignant cal-
cifications and, due to this, the reported sensitivity may be 
slightly overestimated. Another limitation of our study is that 
it is based on data from one Dutch screening center, which 
may not be representative of other breast cancer screening 
programs. In particular, the radiologists in the center oper-
ated at a low recall rate, following the Dutch national breast 
cancer screening policy. Within Europe, the recall rate varies 
from 2 to 6% [16], with the screening program in the Nether-
lands operating at a recall rate of around 2.5%. In the United 
States, recall rates are substantially higher [42]. It is noted, 
however, that the interval cancer rate in the Dutch program 
and the percentage of cancers visible on prior mammograms 
are similar to those reported in the literature [17–28, 43]. 
This shows that our study data are representative of other 
screening practices.
To conclude, 54.5% of calcifications associated with 
cancer could potentially be detected earlier and this may 
substantially reduce the occurrence of invasive cancers in 
the screened population. It is therefore important to develop 
techniques that allow the earlier recall of patients with cal-
cifications without increasing false positives and invasive 
diagnostic procedures to unacceptable levels.
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